CRISPR Therapeutics

CRSP

Market cap $4.68B

CRSP Hedge Fund Activity: Q1 2026 in Review

488 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2026, worth a combined $3.67B — down 8.9% from $4.03B a quarter earlier.

Buyers outnumbered sellers: 79 funds opened new CRSP positions and 57 closed out — a net gain of 22 holders — while 175 added to existing stakes and 116 trimmed.

The largest buyer was Capital World Investors, opening a new position worth an estimated $249M. The largest seller was Capital International Investors, cutting an estimated $248M.

• 488 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2026, up from 479 in Q4 2025.
• Funds reported $3.67B of CRISPR Therapeutics stock for Q1 2026, down 8.9% quarter-over-quarter.
• 79 funds opened new CRISPR Therapeutics positions in Q1 2026 and 57 closed out, a net change of +22 holders.
• The largest CRISPR Therapeutics buyer in Q1 2026 was Capital World Investors, an estimated $249M added.
• The largest CRISPR Therapeutics seller in Q1 2026 was Capital International Investors, an estimated $248M sold.

Based on aggregated 13F filings for Q1 2026.